Reston, VA (October 16, 2026)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
Novel Radiohybrid Ligands Show Promise for Prostate Cancer Therapy
A new radiohybrid ligand pair combines imaging and targeted alpha therapy for prostate cancer. In mice, the therapeutic agent demonstrated 2.2-fold to 3.5-fold higher tumor uptake than a reference agent, with similar effects on tumor growth and survival. The findings support further investigation of this approach.
AI Model Combines Imaging and Clinical Data to Predict Prostate Cancer Survival
A vision–language model integrating PET or SPECT imaging with clinical data predicted 24-month survival in patients with metastatic castration-resistant prostate cancer receiving PSMA-targeted radiopharmaceutical therapy. In a multicenter study, the model achieved 81.8 percent accuracy, outperforming conventional machine-learning approaches and showing promise in external validation.
Radiopharmaceutical Therapy Shows Promise for Refractory Meningiomas
A French multicenter study evaluated 177Lu-DOTATATE in 69 patients with meningiomas that had not responded to previous treatments. Six-month progression-free survival was 70 percent, with a median progression-free survival of 14.6 months. Grade 3 adverse events, mainly lymphopenia, occurred in 16 percent of patients.
New PET/CT Approach Improves Breast Cancer Lesion Detection
A study of 30 patients with breast cancer found that targeted 68Ga-B7H3-BCH PET/CT detected 96.8 percent of lesions, compared with 92.4 percent using standard 18F-FDG PET/CT. Findings from the targeted scan prompted a change in disease stage or treatment in eight patients, suggesting potential clinical value.
PET/MRI Shows Repeatable Uptake Measurements Across Cancer Types
A prospective, two-center study evaluated the repeatability of 18F-FDG PET/MRI measurements across different cancers and scanner models. Within-subject variability for SUVmax ranged from 9.5 percent to 12.3 percent, while SUVpeak variability ranged from 8.8 percent to 9.6 percent. Differences in attenuation-correction maps had minimal impact on measurement repeatability.
Quantitative PET Measures Correlate With Meningioma Receptor Expression
In 44 patients with meningiomas, quantitative measurements from 68Ga-DOTATATE PET/CT strongly correlated with Krenning scores, which assess somatostatin receptor expression. SUVmax and a ratio normalized to the superior sagittal sinus distinguished clinically relevant scoring categories, with areas under the curve reaching 0.98.
PET Tracer Reveals Immunometabolic Activity in Individuals Without Cancer
A study of 20 adults without active malignancy examined normal distribution of 18F-AraG, a PET tracer that accumulates in activated T cells. Uptake patterns varied across brown adipose tissue, bone marrow, breast implant regions, and lungs, with some findings associated with medications or prior respiratory conditions.
Visit the JNM website for the latest research, follow our Twitter and Facebook
